Autobio Diagnostics Co., Ltd (Hereinafter called Autobio) was founded in 1998, headquartered in National Eco & Tech Zone, Zhengzhou.
Autobio specialized in R & D, production, marketing and service of clinical diagnostic products, especially covering immunoassay, microbiology and biochemistry fields. Meanwhile, Autobio is also actively planning the developments in the field of molecular diagnostics and provides a comprehensive solutions for medical laboratories. Autobio was listed on Shanghai Stock Exchange on September 1st, 2016, which is the first IVD manufacturer listed on the main board in Shanghai,China. In 2019, Autobio’s revenue achieved USD412 millions, a year-on-year increase of 38.85%; in 2020, Autobio’s revenue achieved USD459 millions.
R & D experience
2020 operating income
The annual average R&D investment exceeds 10% in recent years; Autobio focuses on team building, with over one third R&D talents among all employees；Compared with the international advanced experience, Autobio applies strict research and development process management; Focusing on the research and development of core raw materials, Autobio has created a diagnostic antibody library for tens of thousands of antigen epitopes, with over 73% self-supply for antigen and antibody, which ensures the stability and safety of supply.Autobio has become one of the leading companies with the most number of registered products and the most comprehensive product catalogue.
Customers come first
value creation for customers
Autobio is always taking product quality and sophisticated manufacturing as development priorities. In terms of reagent production, automatic production line is introduced to improve the level of product automation and work flow, and improve the level of refined management；In terms of instrument manufacturing, Autobio will continue to strengthen the refine management and advocate the spirit of artisans to pursue excellence and continuous improvement; In terms of quality management, Autobio has passed the GMP, ISO9001 and ISO13485 certification, and strict quality management leads to continuously quality improvement.
While focusing on independent innovation and sophisticated manufacturing, Autobio also focuses on global resource integration. Through the integration of research and development innovation resources and even advanced technologies in the industry, Autobio can provide more abundant products for medical laboratories.
Autobio's marketing network covers the whole country, and our products have entered more than ten thousands medical institutions. In overseas markets, Autobio’s products has performed enormous potential, exporting to over 80 countries,such as Europe, Asia, Middle East, South America，Africa etc.
Under constructed Autobio industrial park covers an area of more than 250 acres, with construction area of more than 500,000 square meters(more than 100,000 square meters have been put into use). Upon completion, it will have over US$ 15 billion production capacity, and will become one of the largest IVD bases in China.